Despite major advances in diabetes care and technology, the current clinic-based model is costly and at times inefficient with limited scalability. Joslin Home model (JH) includes 5 new pillars of diabetes interactions: short visits of 5-15 min conducted by telehealth, more frequent visits with a multidisciplinary team (MD, NP, RD, CDE, exercise physiologist (EP), and behavioral therapist (BT)), direct 2-way electronic scheduling, brief documentations and easy one-step billing.

In this 6-month pilot study, we tested the feasibility of JH among 17 patients with critically high A1C (average 9.5±1.6%), age 62±14 yrs, weight 225±35 lbs and 70.6% treated with insulin. Cellular glucose meter, body-weight scale and BP kit were delivered to subjects’ homes for self-reporting. Patients were instructed to self-schedule/cancel appointments using an electronic calendar. Five precise questions were asked before each encounter. Providers were asked to briefly document encounters.

Results: Virtual visits were completed in an average of 16 min, MDs and NPs concluded them in <15 min (∼11 min), but BT needed the longest time (20-30 min). Patients had an average of one encounter/week. Higher visit frequency was only seen in <25% of patients. Around 76% of scheduled encounters were completed (range 56-100%). Visit cancellation was the lowest with RD and EP (10-18%) and highest with BT and CDE (29-31%). A1C dropped significantly by 1.2% (to 8.2±1.5%, p<0.001). Patients’ satisfaction was high and they were willing to pay out-of-pocket of $50-200/encounter. We conclude that JH model is potentially acceptable alternative to clinic-based model and that is potentially scalable for remote and underserved areas where multidisciplinary approach is lacking. Frequent and short encounters of <20 min resulted in significant A1C improvement. JH may be ideal for high-risk patients who require frequent encounters with a diabetes team. Larger adoption in a randomized clinical study warrants consideration.


O. Hamdy: Consultant; Self; Abbott, AstraZeneca, Merck & Co., Inc., Sanofi-Aventis. Research Support; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Healthimation, LLC. J. Mitri: Consultant; Spouse/Partner; Janssen Pharmaceuticals, Inc., kymera. Consultant; Self; national dairy council/local dairy council. Research Support; Spouse/Partner; AbbVie Inc., beigene, Janssen Pharmaceuticals, Inc. Research Support; Self; Kowa Pharmaceuticals America, Inc., national dairy council. Research Support; Spouse/Partner; pharma cyclic, TG therapeutics. A. Barrett: None. R.A. Gabbay: Advisory Panel; Self; FormHealth, Health Reveal, Lark, Onduo, Vida Health.


Joslin Diabetes Center

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at